At close: December 13 at 4:00:01 PM EST
After hours: 7:00:41 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.92 | -0.77 | -4.05 | -2.16 |
| Low Estimate | -0.92 | -0.77 | -4.05 | -2.16 |
| High Estimate | -0.92 | -0.77 | -4.05 | -2.16 |
| Year Ago EPS | -8.14 | -1.11 | -8.48 | -4.05 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | -- | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | -- | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.6 | -1.18 | -0.98 | -1 |
| EPS Actual | -8.14 | -1.11 | -1.01 | -1.03 |
| Difference | -6.54 | 0.07 | -0.03 | -0.03 |
| Surprise % | -408.75% | 5.93% | -3.06% | -3.00% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.92 | -0.77 | -4.05 | -2.16 |
| 7 Days Ago | -0.76 | -0.66 | -3.78 | -2.12 |
| 30 Days Ago | -0.76 | -0.66 | -3.78 | -2.12 |
| 60 Days Ago | -0.76 | -0.66 | -3.78 | -2.12 |
| 90 Days Ago | -0.76 | -0.66 | -3.78 | -2.12 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | 1 | 1 | 1 | 1 |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| PCSA | 88.70% | 30.63% | 52.24% | 46.67% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/5/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/20/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/19/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/12/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/13/2024 |
Related Tickers
PBM Psyence Biomedical Ltd.
1.8500
-9.31%
SLXN Silexion Therapeutics Corp
3.5200
+5.39%
PALI Palisade Bio, Inc.
1.7700
-25.00%
IPHA Innate Pharma S.A.
3.0200
+96.10%
CRDF Cardiff Oncology, Inc.
3.9200
+19.88%
SONN Sonnet BioTherapeutics Holdings, Inc.
1.8100
+2.26%
TRVI Trevi Therapeutics, Inc.
4.1700
+15.83%
CMRX Chimerix, Inc.
2.9500
+0.34%
SXTP 60 Degrees Pharmaceuticals, Inc.
1.4100
-14.55%
CDIO Cardio Diagnostics Holdings, Inc.
1.2600
+5.00%